Modulating the TREGs Pathway in ALS: Unveiling Innate Immunity’s Role in Neurodegeneration
Time: 1:30 pm
day: Conference Day Two Track B PM
Details:
- To explore the role of regulatory T cell (Treg) dysfunction in neuroinflammation and as a contributing factor in the pathogenesis of ALS
- To discuss ex vivo and in vivo therapeutic approaches that target Treg dysfunction to suppress neuroinflammation and potentially slow disease progression in ALS and other neurodegenerative diseases
- To unveil plans for a phase 2 study evaluating COYA 302 in ALS
